{"id":203897,"name":"ADMA BIOLOGICS, INC.","slug":"adma-biologics-inc","state":"FL","country":"United States of America","description":"Biopharmaceutical company","totalSpending":120000,"filings":24,"yearlySpending":[{"year":2020,"income":0},{"year":2021,"income":30000},{"year":2022,"income":40000},{"year":2023,"income":30000},{"year":2024,"income":10000},{"year":2025,"income":10000}],"issues":[{"code":"HCR","display":"Health Issues"},{"code":"DEF","display":"Defense"}],"firms":["AMERICAN DEFENSE INTERNATIONAL, INC."],"lobbyists":["VAN HIPP"],"govEntities":["Health & Human Services, Dept of (HHS)","HOUSE OF REPRESENTATIVES","Natl Security Council (NSC)","SENATE","White House Office"],"sampleDescriptions":["Issues related to the treatment of immune compromised patients who have documented COVID-19 infections.","Meetings with officials relating to plasma.","Meetings with officials relating to plasma.","National Defense Authorization Act for FY22, provisions relating to plasma-derived antibody products.\nDepartment of Defense Appropriations Act for FY22, provisions relating to plasma-derived antibody ","Labor, Health and Human Services, Education and Related Agencies Appropriations Bill for FY22, provisions relating to plasma-derived antibody products."]}